Beyond inhaled medications: precision medicine and biologic therapies targeting the IL-33/TSLP/type 2 axis in COPD.

Front Immunol · 2026 · PMC12916659 · PMID 41727449

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

did not reach statistical significanceno p-value reported

Specifically, benralizumab demonstrated a borderline significant reduction in exacerbation risk (rate ratio 0.92; 95% CI: 0.85-1.00), while mepolizumab exhibited a trend toward lower exacerbation risk that did not reach statistical significance (rate ratio 0.90; 95% CI: 0.77-1.06) ( 44 ).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.